NBIX News and Press, Neurocrine Biosciences Inc. From 05/02/22

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week PR Newswire States Across the Country Declare First Week of May (1-7) Tardive Dyskinesia Awareness Week to Raise Awareness of This Burdensome and Of...

As a potential big winner, Crinetics Pharmaceuticals executes prudent corporate strategies that focus on orphan diseases and established biological pathways. The lead medicine (paltusotine) demonstrated strong efficacy in its Phase 2 (ACROBAT Edge) trial for acromegaly. I expect s...

The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix will ultimately gain approval for endometriosis (perhaps in either Q3 or Q4 this year). ...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy underperformed during a pronounced rotation ...

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results PR Newswire Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc....

Goldman Sachs equity strategists stressed the importance of pricing power for companies given a four-decade high in inflation and rising commodities prices. "Pricing power will become increasingly important in the face of continued inflation and cost pressures," David Kostin, chief U.S. equit...

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022 PR Newswire - Valbenazine Met the Primary Endpoint of Significant ( p <0.0001) Improvement in Chorea Severity ve...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan PR Newswire SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its...

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022 PR Newswire SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc...